Ch1: Laboratory Assessment of Lipoproteins in Diabetes
David R. Sullivan
Barry Lewis
Ch2: Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance Diabetes
Michael Cobble
Patrick D. Mize
Eliot A. Brinton
Ch3: Insulin Resistance and Atherosclerosis
Kamalpreet Singh
Vasudevan A. Raghavan
Ch4: Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes
Thomas D. Dayspring
Ch5: Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetes
Gerald H. Tomkin
Daphne Owens
Ch6: Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States
Angela Pirillo
Giuseppe D. Norata
Alberico L. Catapano
Ch7: Lipoprotein(a): Structure, Metabolism and Pathophysiology
Alicia J. Jenkins
Karam M. Kostner
Gerhard M. Kostner
Ch8: Lipoprotein Glycation in Diabetes Mellitus
Alicia J. Jenkins
Richard L. Klein
Andrzej S. Januszewski
Ch9: Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus
Marielle Kaplan
Michael Aviram
Tony Hayek
Ch10: The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes
Maria F. Lopes-Virella
Gabriel Virella
Ch11: Lipid - Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes
Narin Osman
Peter J.
Little
Ch12: Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus
Richard L. Klein
Ch13: Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy
Sandra J. Hamilton
Gerald F. Watts
Ch14: Lipoproteins and Diabetic Nephropathy
Ville-Petteri Mäkinen
Nina Tolonen
Per-Henrik Groop
Ch15: Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy
Mingyuan Wu
Timothy J. Lyons
Ch16: Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes
Peter Clifton
Ch17: About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus
Anthony Keech
Alicia J. Jenkins
Val Gebski
Ch18: Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients
Seth S. Martin
Parag H. Joshi
Steven R. Jones
Ch19: The PPAR System in Diabetes
Jean Claude Ansquer
Christelle Foucher
Ch20: Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients
Eliot A. Brinton
Ch21: Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients
Henry A. Tran
Arthur Z. Schwartzbard
James A. Underberg
Ch22: Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus
Harold Bays
Ch23: Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Peter J. Little
Alan Chait
Andrzej S. Januszewski
Alex Bobik
David O'Neal
Alicia J. Jenkins
About the Author: Alicia Jenkins, MBBS, MD, FRACP, FRCP
University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USA
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
CGH Medical Center, Sterling, IL
University of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, IL
Michigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USA
Timothy J. Lyons, MD, FRCP
University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA
